Clinical scenario 1 - BRAFKIAA-1549 fusion

Author(s):

The panel examines a specific patient case, offering detailed insights into their decision-making process and treatment approaches for patients with pediatric low-grade gliomas (pLGG).

EP: 1.Overview of pLGG presentation and categorization

EP: 2.Molecular Characterization of pLGG

EP: 3.Less Common Molecular Alterations in pLGG and Testing Recommendations

EP: 4.Standard of care for frontline treatment of non-V600E-specific pLGG tumors

EP: 5.Ongoing clinical trials for frontline treatment of non-V600E-specific pLGG tumors

EP: 6.Current Treatment of Patients with NF1 pLGG

EP: 7.Standard of Care Pptions Specific for Frontline Treatment of BRAF V600E-Mutated pLGG

EP: 8.Treatment Considerations for Progressive pLGG

EP: 9.Radiation and Targeted Therapies for Progressive pLGG

EP: 10.The Role of Tovorafenib in Treatment of Progressive pLGG

EP: 11.Clinical Trials to Increase Treatment Options in the Progressive Setting

Now Viewing

EP: 12.Clinical scenario 1 - BRAFKIAA-1549 fusion

EP: 13.Alternatives and Considerations for Clinical Scenario 1

EP: 14.Clinical Scenario 2 - BRAFV600E

EP: 15.Potential Adverse Events With Targeted Therapies

EP: 16.Clinical Insights: Looking Forward for pLGG

Of the possible options, what treatment approach would you select for this patient?
What key clinical or patient-specific factors informed this choice?
Please consider and discuss alternate scenarios:
What if this patient had received frontline chemotherapy (instead of selumetinib) and then progressed? How would this impact your treatment decision?
What if the patient was currently on a MEKi, would you switch?